Literature DB >> 8807073

Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Canadian Ciprofloxacin Study Group.

J M Blondeau1, Y Yaschuk.   

Abstract

We tested 4,507 microorganisms, from 15 Canadian medical centers, against ciprofloxacin and several other antimicrobial agents to determine the in vitro susceptibilities. Overall, susceptibility of members of the family Enterobacteriaceae to ciprofloxacin was 97%; Moraxella and Haemophilus spp. had susceptibilities of 98 and 99%, respectively; and P. aeruginosa and S. aureus had susceptibilities of 79 and 96%, respectively.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8807073      PMCID： PMC163406     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Ciprofloxacin-resistant methicillin-resistant Staphylococcus aureus in an acute-care hospital.

Authors:  M C Raviglione; J F Boyle; P Mariuz; A Pablos-Mendez; H Cortes; A Merlo
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Resistance development to fluoroquinolones in Europe.

Authors:  B Wiedemann; M T Zühlsdorf
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

3.  Canadian survey of antimicrobial resistance in Klebsiella spp. and Enterobacter spp. The Canadian Antimicrobial Resistance Study Group.

Authors:  B W Toye; S R Scriver; D E Low
Journal:  J Antimicrob Chemother       Date:  1993-11       Impact factor: 5.790

4.  Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Canadian Ofloxacin Study Group.

Authors:  D J Hoban; R N Jones
Journal:  Chemotherapy       Date:  1995 Jan-Feb       Impact factor: 2.544

5.  Quinolone resistance. Susceptibility data from a 300-bed community hospital.

Authors:  M F Parry; K B Panzer; M E Yukna
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

6.  Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States.

Authors:  V G Coronado; J R Edwards; D H Culver; R P Gaynes
Journal:  Infect Control Hosp Epidemiol       Date:  1995-02       Impact factor: 3.254

7.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

8.  Ciprofloxacin: an oral quinolone for the treatment of infections with gram-negative pathogens. Committee on Antimicrobial Agents. Canadian Infectious Disease Society.

Authors:  T J Louie
Journal:  CMAJ       Date:  1994-03-01       Impact factor: 8.262

9.  Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group.

Authors:  S Chamberland; J L'Ecuyer; C Lessard; M Bernier; P Provencher; M G Bergeron
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

10.  Comparative in vitro studies with 4-quinolone antimicrobials.

Authors:  D Felmingham; M D O'Hare; M J Robbins; R A Wall; A H Williams; A W Cremer; G L Ridgway; R N Grüneberg
Journal:  Drugs Exp Clin Res       Date:  1985
View more
  7 in total

1.  Ciprofloxacin-resistant Escherichia coli in hospital wastewater of Bangladesh and prediction of its mechanism of resistance.

Authors:  Farhima Akter; M Ruhul Amin; Khan Tanjid Osman; M Nural Anwar; M Manjurul Karim; M Anwar Hossain
Journal:  World J Microbiol Biotechnol       Date:  2011-09-09       Impact factor: 3.312

2.  In vitro activity of cefepime against multidrug-resistant Gram-negative bacilli, viridans group streptococci and Streptococcus pneumoniae from a cross-Canada surveillance study.

Authors:  D E Low; J de Azavedo; R Davidson
Journal:  Can J Infect Dis       Date:  1999-03

3.  Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.

Authors:  D F Sahm; I A Critchley; L J Kelly; J A Karlowsky; D C Mayfield; C Thornsberry; Y R Mauriz; J Kahn
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

4.  Canadian Multicenter Susceptibility Study, with a focus on cephalosporins, from 15 Canadian medical centers. The Canadian Multicenter Study Group.

Authors:  J M Blondeau; Y Yaschuk
Journal:  Antimicrob Agents Chemother       Date:  1997-12       Impact factor: 5.191

5.  Comparison of agar dilution, disk diffusion, MicroScan, and Vitek antimicrobial susceptibility testing methods to broth microdilution for detection of fluoroquinolone-resistant isolates of the family Enterobacteriaceae.

Authors:  C D Steward; S A Stocker; J M Swenson; C M O'Hara; J R Edwards; R P Gaynes; J E McGowan; F C Tenover
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

6.  Streptococcus pneumoniae, Brooklyn, New York: fluoroquinolone resistance at our doorstep.

Authors:  John Quale; David Landman; Jayashree Ravishankar; Carlos Flores; Simona Bratu
Journal:  Emerg Infect Dis       Date:  2002-06       Impact factor: 6.883

7.  Analysis of the Occurrence of Antibiotic Resistant Bacteria in the Hospital's Effluent and its Receiving Environment.

Authors:  A M Masudul Azad Chowdhury; Kazi Nayeem Uddin
Journal:  Microbiol Insights       Date:  2022-02-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.